Zytiga Prolongs Prostate Cancer Survival

ORLANDO (MedPage Today) -- Survival improved and disease progression slowed in men with metastatic castration-resistant prostate cancer treated in first line with abiraterone acetate (Zytiga).
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news